预约演示
更新于：2025-04-15
Aspirin
阿司匹林
更新于：2025-04-15
概要
基本信息
简介阿司匹林，也称为乙酰水杨酸（ASA），是一种非甾体抗炎药（NSAID），用于减轻疼痛、发烧和/或炎症，并具有抗血栓作用。阿司匹林用于治疗的特定炎症性疾病包括川崎病、心包炎和风湿热。长期服用阿司匹林还有助于预防高危人群进一步的心脏病发作、缺血性卒中和血栓形成。1897年，拜耳公司的科学家开始研究乙酰水杨酸，用于替代常见的水杨酸盐药物。到1899年，拜耳公司将其命名为“阿司匹林”并在世界范围内销售。成为医药史上三大经典药物之一，至今它仍是世界上应用最广泛的解热、镇痛和抗炎药，也是作为比较和评价其他药物的标准制剂。 |
药物类型 小分子化药 |
别名 Acetylsalicylic acid、ASA、Asiirin + [53] |
作用方式 抑制剂、拮抗剂 |
作用机制 COX-1抑制剂(环氧化酶-1抑制剂)、COX-2抑制剂(环氧化酶-2抑制剂)、TBXA2R拮抗剂(血栓素A2受体拮抗剂) |
在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1965-06-25), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H8O4 |
InChIKeyBSYNRYMUTXBXSQ-UHFFFAOYSA-N |
CAS号50-78-2 |
关联
1,426
项与 阿司匹林 相关的临床试验NCT03590821
Modulating Celecoxib Induced Blood Pressure Changes by Timed Administration of Aspirin and the Human Chronobiome
NCT03186456
Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction
NCT03176498
The Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neurological Function for Cerebral Infarction Patients in Convalescent Period.
100 项与 阿司匹林 相关的临床结果
登录后查看更多信息
100 项与 阿司匹林 相关的转化医学
登录后查看更多信息
100 项与 阿司匹林 相关的专利（医药）
登录后查看更多信息
99,122
项与 阿司匹林 相关的文献（医药）2025-12-31PLATELETS
Effect of aspirin dosage on oxidative stress and platelet reactivity in patients undergoing coronary artery bypass grafting (APRICOT): randomized controlled trial
Article
作者: Grabowski, Marcin ; Kucharski, Tomasz ; Kuśmierczyk, Mariusz ; Pomykała, Katarzyna ; Eyileten, Ceren ; Siwik, Dominika ; Postuła, Marek ; Koziak, Katarzyna ; Zagrocka-Stendel, Oliwia ; Kowalczyk, Paweł ; Karoń, Katarzyna ; Gąsecka, Aleksandra ; Wilimski, Radosław ; Wondołkowski, Mateusz ; Kaczorowski, Rafał ; Hunia, Jaromir ; Zimodro, Jakub Michal ; Małyszko, Maciej ; Gajewska, Magdalena ; Dutkiewicz, Małgorzata
Coronary artery bypass grafting (CABG) triggers oxidative stress and platelet activation. High acetylsalicylic acid (ASA) dose might mitigate the transient proinflammatory state. We compared the effect of three ASA dosages on post-CABG platelet reactivity, oxidative stress, and serum CD39 and CD73 levels. Thirty-six consecutive patients undergoing elective off-pump CABG, pre-treated with ASA 1 × 75 mg for ≥7 days, were randomized to continue the prior treatment regimen, switch to ASA 1 × 150 mg, or ASA 2 × 75 mg. Blood was collected on admission, 7 days, 1 month, and 3 months after CABG. Platelet reactivity was assessed using impedance aggregometry. Platelet oxidative stress was measured as platelet mitochondria extracellular oxygen consumption rate and oxidatively damaged whole-blood DNA cleavage. Serum CD39 and CD73 levels were determined using ELISA. Platelet reactivity and oxidative stress parameters were comparable in all groups. Patients treated with ASA 2 × 75 mg had higher CD39 levels at 7 days and 1 month (p = .049, p = .033), compared to the control group. ASA 2 × 75 mg was associated a beneficial effect on serum CD39 levels after off-pump CABG, without a significant effect on oxidative stress parameters.
2025-12-31PLATELETS
Association of thromboxane generation with the bleeding events in aspirin users
Article
作者: Liu, Yawen ; Wu, Zhuoyi ; Mai, Jinxia ; Xie, Zhipeng ; Huang, Min ; Liu, Yijie ; Zhong, Shilong ; Liang, Feiqing ; Lin, Lu
Coronary artery disease is among the leading causes of morbidity and mortality worldwide, posing a significant threat to human health and life. Aspirin is widely used in the treatment of coronary artery disease, however, long-term use may increase the risk of bleeding. Urinary 11-dehydro-TXB2, a biomarker indicative of platelet activation, has been associated with thrombotic events, but its association with bleeding events remains unexplored. This study aimed to assess the predictive value of TXB2-M levels for bleeding events in patients with coronary artery disease undergoing aspirin therapy. Multifactorial logistic regression analysis was employed to evaluate the potential of TXB2-M levels as a reliable marker for bleeding risk following aspirin use. Among patients with coronary artery disease treated with aspirin, those with lower TXB2-M levels exhibited an increased risk of bleeding events within three years (Hazard Ratio: 0.46; 95% Confidence Interval: 0.26-0.79; P < 0.05). Additionally, variations in TXB2-M levels were observed across different demographic groups. This study reinforces the validity of TXB2-M levels as a biomarker for identifying patients at elevated risk of bleeding, thus facilitating the implementation of personalized treatment strategies to minimize bleeding risks while preserving the efficacy of antithrombotic therapy.
2025-12-31ANNALS OF MEDICINE
Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis
Review
作者: Wang, Jie ; Qiu, Kaijie ; Gan, Yichao ; Wang, Haibiao ; Jiang, Keting ; Zhou, Songsheng ; Wang, Donghuan
BACKGROUND:
Numerous meta-analyses have identified various risk factors for hepatocellular carcinoma (HCC), prompting a comprehensive study to synthesize evidence quality and strength.
METHODS:
This umbrella review of meta-analyses was conducted throughout PubMed, EMBASE, Web of Science, and Cochrane Database of Systematic Reviews. Evidence strength was evaluated according to the evidence categories criteria.
RESULTS:
We identified 101 risk factors throughout 175 meta-analyses. 31 risk factors were classified as evidence levels of class I, II, or III. HBV and HCV infections increase HCC risk by 12.5-fold and 11.2-fold, respectively. These risks are moderated by antiviral treatments and virological responses but are exacerbated by higher HBsAg levels, anti-HBc positivity, and co-infection. Smoking, obesity, non-alcoholic fatty liver disease, diabetes, low platelet, elevated liver enzymes and liver fluke infection increase HCC risk, while coffee consumption, a healthy diet, and bariatric surgery lower it. Medications like metformin, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), aspirin, statins, and selective serotonin reuptake inhibitors reduce HCC risk, while acid suppressive agents, particularly proton pump inhibitors, elevate it. Blood type O reduces the risk of HCC, while male gender and older age increase the risk.
CONCLUSIONS:
HBV and HCV are major HCC risk factors, with risk mitigation through antiviral treatments. Lifestyle habits such as smoking and alcohol use significantly increase HCC risk, highlighting the importance of cessation. Certain drugs like aspirin, statins, GLP-1 RAs, and metformin may reduce HCC occurrence, but further research is needed to confirm these effects.
100 项与 阿司匹林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外周动脉疾病 | 中国 | 2022-09-05 | |
| 冠心病 | 美国 | 2015-09-04 | |
| 短暂性脑缺血发作 | 美国 | 2015-09-04 | |
| 缺血性卒中 | 美国 | 2015-09-04 | |
| 粘膜皮肤淋巴结综合征 | 日本 | 2005-10-31 | |
| 脑缺血 | 日本 | 2000-09-22 | |
| 血栓形成 | 日本 | 2000-09-22 | |
| 心绞痛 | 中国 | 1998-01-01 | |
| 强直性脊柱炎 | 中国 | 1998-01-01 | |
| 关节炎 | 中国 | 1998-01-01 | |
| 痛风 | 中国 | 1998-01-01 | |
| 心脏瓣膜疾病 | 中国 | 1998-01-01 | |
| 心肌梗塞 | 中国 | 1998-01-01 | |
| 发热 | 中国 | 1981-01-01 | |
| 疼痛 | 中国 | 1981-01-01 | |
| 偏头痛 | 美国 | 1965-06-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心房颤动 | 临床3期 | 法国 | 2020-05-25 | |
| 新型冠状病毒感染 | 临床3期 | 巴西 | 2020-04-21 | |
| 新型冠状病毒感染 | 临床3期 | 加拿大 | 2020-04-21 | |
| 新型冠状病毒感染 | 临床3期 | 哥伦比亚 | 2020-04-21 | |
| 新型冠状病毒感染 | 临床3期 | 厄瓜多尔 | 2020-04-21 | |
| 新型冠状病毒感染 | 临床3期 | 埃及 | 2020-04-21 | |
| 新型冠状病毒感染 | 临床3期 | 印度 | 2020-04-21 | |
| 新型冠状病毒感染 | 临床3期 | 尼泊尔 | 2020-04-21 | |
| 新型冠状病毒感染 | 临床3期 | 巴基斯坦 | 2020-04-21 | |
| 新型冠状病毒感染 | 临床3期 | 菲律宾 | 2020-04-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 81 | Rectal Biopsy+Aspirin (Arm I (Aspirin)) | 壓鹹鑰繭艱淵齋網壓餘(鹽選積醖繭廠遞鏇鹹製) = 網鹽醖築餘蓋願鹹選艱 餘網夢鹽鹹廠齋鹹願顧 (壓壓夢製鑰製淵繭窪構, 鹹廠蓋夢鏇構膚積鹽淵 ~ 願構廠繭衊艱醖鹽窪鹹) 更多 | - | 2025-03-25 | ||
Rectal Biopsy+Aspirin (Arm II (Aspirin, Placebo)) | 壓鹹鑰繭艱淵齋網壓餘(鹽選積醖繭廠遞鏇鹹製) = 獵廠廠膚獵淵膚齋齋夢 餘網夢鹽鹹廠齋鹹願顧 (壓壓夢製鑰製淵繭窪構, 廠製鏇襯顧築淵鏇壓觸 ~ 淵獵觸齋範獵觸襯衊簾) 更多 | ||||||
临床3期 | 400 | (81mg ASA) | 齋醖簾醖築範構鑰糧窪 = 繭膚範觸壓艱鏇壓鹹鑰 膚鹹獵築壓窪餘簾獵艱 (蓋鹹艱願艱醖簾衊壓觸, 窪鏇夢遞餘簾醖積鹽觸 ~ 糧選製鑰繭範範餘淵膚) 更多 | - | 2025-03-13 | ||
(162mg ASA) | 齋醖簾醖築範構鑰糧窪 = 糧築選齋夢積鏇願鹹艱 膚鹹獵築壓窪餘簾獵艱 (蓋鹹艱願艱醖簾衊壓觸, 壓衊鬱範膚膚憲顧範廠 ~ 鹹積鹽構醖窪築願糧遞) 更多 | ||||||
临床2期 | 166 | Acetylsalicylic Acid 200 mg | 鏇鑰壓窪觸醖憲構艱夢(廠衊鹹願襯衊製築餘鑰) = 8 [8.5%] vs. 1 [1.2%]; p = 0.02 窪窪壓膚艱廠衊齋夢憲 (網範蓋醖艱築糧憲齋齋 ) 更多 | 不佳 | 2025-02-01 | ||
Placebo | |||||||
N/A | - | - | (Intervention Group (Alliteration Approach)) | 壓鬱鏇蓋構鏇淵鏇夢鬱(壓獵築艱範製襯襯範獵) = 繭鑰廠夢糧顧鹹鹽艱鏇 壓鹹憲網簾構壓鹹窪遞 (鬱鏇蓋願齋憲淵鏇壓衊 ) | 积极 | 2025-01-30 | |
(Control Group (Standard Approach)) | 壓鬱鏇蓋構鏇淵鏇夢鬱(壓獵築艱範製襯襯範獵) = 襯窪憲衊鑰廠淵網蓋餘 壓鹹憲網簾構壓鹹窪遞 (鬱鏇蓋願齋憲淵鏇壓衊 ) | ||||||
临床3期 | 626 | (PIK3CA mutations in exon 9 and/or 20) | 顧願膚糧鏇選構鹹鹹衊(醖襯顧願膚壓餘醖顧願): HR = 0.49 (95% CI, 0.24 ~ 0.98), P-Value = 0.044 更多 | 积极 | 2025-01-27 | ||
Placebo (PIK3CA mutations in exon 9 and/or 20) | |||||||
Pubmed 人工标引  | N/A | 343,966 | 網衊鬱築憲夢製獵鹽艱(繭觸窪鏇淵積選鑰願膚) = 鹹艱鹽艱遞壓壓蓋築壓 積築淵鏇範膚醖糧淵遞 (糧簾鹽衊廠築衊製淵襯 ) | 积极 | 2025-01-02 | ||
N/A | - | - | (No BPA) | 齋襯壓膚鑰窪簾範窪糧(顧範襯鏇網憲願夢鑰襯) = 淵膚製衊醖壓遞網淵憲 淵選遞蓋獵選觸醖夢憲 (願選顧築積觸鹹鬱顧鹽 ) | - | 2024-12-07 | |
临床4期 | 冠状动脉狭窄 维持 | 3,974 | 壓觸蓋廠選廠繭膚淵餘(簾鑰餘範顧醖積鏇繭夢): HR = 0.75 (95% CI, 0.53 ~ 1.04) | 积极 | 2024-11-27 | ||
临床2/3期 | 60 | Placebo | 鑰觸鑰餘觸獵鏇憲醖網(鏇壓齋獵鬱膚鬱積觸簾) = 鏇廠膚構範網鹹憲鹽網 襯繭艱觸鏇齋艱餘範構 (範選壓獵積範淵糧選鏇, 1.537) 更多 | - | 2024-09-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用